Search

Your search keyword '"Amorim, Sandy"' showing total 21 results
Start Over Author "Amorim, Sandy" Search Limiters Full Text
21 results on '"Amorim, Sandy"'

1. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort

Author

Ghesquières, Hervé, Cherblanc, Fanny, Belot, Aurélien, Micon, Sophie, Bouabdallah, Krimo K., Esnault, Cyril, Fornecker, Luc-Matthieu, Thokagevistk, Katia, Bonjour, Maxime, Bijou, Fontanet, Haioun, Corinne, Morineau, Nadine, Ysebaert, Loïc, Damaj, Gandhi, Tessoulin, Benoit, Guidez, Stéphanie, Morschhauser, Franck, Thiéblemont, Catherine, Chauchet, Adrien, Gressin, Rémy, Jardin, Fabrice, Fruchart, Christophe, Labouré, Gaëlle, Fouillet, Ludovic, Lionne-Huyghe, Pauline, Bonnet, Antoine, Lebras, Laure, Amorim, Sandy, Leyronnas, Cécile, Olivier, Gaelle, Guieze, Romain, Houot, Roch, Launay, Vincent, Drénou, Bernard, Fitoussi, Olivier, Detourmignies, Laurence, Abraham, Julie, Soussain, Carole, Lachenal, Florence, Pica, Gian Matteo, Fogarty, Patrick, Cony-Makhoul, Pascale, Bernier, Adeline, Le Guyader-Peyrou, Sandra, Monnereau, Alain, Boissard, Frédéric, Rossi, Cédric, and Camus, Vincent

Published
2024
Full Text
View/download PDF

2. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Author

Aubrais, Raphaelle, Bouabdallah, Krimo, Chartier, Loic, Herbaux, Charles, Banos, Anne, Brice, Pauline, Sibon, David, Schiano, Jean Marc, Cluzeau, Thomas, Laribi, Kamel, Le Calloch, Ronan, Bellal, Mathieu, Delapierre, Baptiste, Daguindau, Nicolas, Amorim, Sandy, Agbetiafa, Kossi, Chauchet, Adrien, Besson, Caroline, Durot, Eric, Bonnet, Christophe, Fouillet, Ludovic, Bijou, Fontanet, Tournilhac, Olivier, Gaulard, Philippe, Parrens, Marie-Cécile, and Damaj, Gandhi

Published
2023
Full Text
View/download PDF

3. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort

Author

Ghesquieres, Herve, primary, Cherblanc, Fanny, additional, Belot, Aurelien, additional, Micon, Sophie, additional, Bouabdallah, Krimo, additional, Esnault, Cyril, additional, Fornecker, Luc-Matthieu, additional, Thokagevistk, Katia, additional, Bonjour, Maxime, additional, Bijou, Fontanet, additional, Haioun, Corinne, additional, Morineau, Nadine, additional, Ysebaert, Loïc, additional, Damaj, Gandhi, additional, Tessoulin, Benoit, additional, Guidez, Stéphanie, additional, Morschhauser, Franck, additional, Thieblemont, Catherine, additional, Chauchet, Adrien, additional, Gressin, Remy, additional, Jardin, Fabrice, additional, Fruchart, Christophe, additional, Labouré, Gaelle, additional, Fouillet, Ludovic, additional, Lionne-Huyghe, Pauline, additional, Bonnet, Antoine, additional, Lebras, Laure, additional, Amorim, Sandy, additional, Leyronnas, Cecile, additional, Olivier, Gaelle, additional, Guieze, Romain, additional, Houot, Roch, additional, Launay, Vincent, additional, Drénou, Bernard, additional, Fitoussi, Olivier, additional, Detourmignies, Laurence, additional, Abraham, Julie, additional, Soussain, Carole, additional, Lachenal, Florence, additional, Pica, Gian Matteo, additional, Fogarty, Patrick, additional, Cony-Makhoul, Pascale, additional, Bernier, Adeline, additional, Le Guyader-Peyrou, Sandra, additional, Monnereau, Alain, additional, Boissard, Frédéric, additional, Rossi, Cédric, additional, and Camus, Vincent, additional

Published
2023
Full Text
View/download PDF

4. Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients

Author

Milcent, Benoit, Josseaume, Nathalie, Riller, Quentin, Giglioli, Ilenia, Rabia, Emilia, Deligne, Claire, Latouche, Jean-Baptiste, Hamieh, Mohamad, Couture, Alexandre, Toutirais, Olivier, Lone, Yu-Chun, Jeger-Madiot, Raphaël, Graff-Dubois, Stéphanie, Amorim, Sandy, Loiseau, Pascale, Toubert, Antoine, Brice, Pauline, Thieblemont, Catherine, Teillaud, Jean-Luc, and Sibéril, Sophie

Published
2019
Full Text
View/download PDF

5. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA

Author

Aubrais, Raphaelle, primary, Bouabdallah, Krimo, additional, chartier, loic, additional, Herbaux, Charles, additional, Banos, Anne, additional, Brice, Pauline, additional, Sibon, David, additional, Schiano, Jean Marc, additional, Cluzeau, Thomas, additional, Laribi, Kamel, additional, LE CALLOCH, Ronan, additional, bellal, Mathieu, additional, Delapierre, Baptiste, additional, daguindau, nicolas, additional, Amorim, Sandy, additional, Agbetiafa, Kossi, additional, Chauchet, Adrien, additional, besson, caroline, additional, Durot, Eric, additional, Bonnet, Christophe, additional, Fouillet, Ludovic, additional, Bijou, Fontanet, additional, Tournilhac, Olivier, additional, Gaulard, Philippe, additional, Parrens, Marie-Cécile, additional, and Damaj, Gandhi, additional

Published
2022
Full Text
View/download PDF

7. Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

Author

Bouabdallah, Krimo, primary, Aubrais, Raphaëlle, additional, Chartier, Loïc, additional, Herbaux, Charles, additional, Banos, Anne, additional, Brice, Pauline, additional, Ochmann, Marlene, additional, Sibon, David, additional, Schiano De Colella, Jean Marc, additional, Cluzeau, Thomas, additional, Laribi, Kamel, additional, Le Calloch, Ronan, additional, Bellal, Mathieu, additional, Daguindau, Nicolas, additional, Amorim, Sandy, additional, Agbetiafa, Kossi, additional, Chauchet, Adrien, additional, Hammami, Marwa, additional, Durot, Eric, additional, Bonnet, Christophe, additional, Robles, Margot, additional, Fouillet, Ludovic, additional, Bijou, Fontanet, additional, Tournilhac, Olivier, additional, Gaulard, Philippe, additional, Parrens, Marie, additional, Milpied, Noel-Jean, additional, and Damaj, Gandhi Laurent, additional

Published
2021
Full Text
View/download PDF

8. Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

Author

Lazarovici, Julien, primary, Amorim, Sandy, additional, Bouabdallah, Krimo, additional, Guidez, Stéphanie, additional, Molina, Lysiane, additional, Morschhauser, Franck, additional, Gac, Anne-Claire, additional, Gastinne, Thomas, additional, Laribi, Kamel, additional, Launay, Vincent, additional, Slama, Bohrane, additional, Belmecheri, Nawel, additional, Casasnovas, René-Olivier, additional, Corby, Anne, additional, Durot, Eric, additional, Feugier, Pierre, additional, Nicolas-Virelizier, Emmanuelle, additional, Sibon, David, additional, Berriolo-Riedinger, Alina, additional, Edeline, Veronique, additional, Vander Borght, Thierry, additional, Damotte, Diane, additional, Traverse-Glehen, Alexandra, additional, Andre, Marc, additional, and Ribrag, Vincent, additional

Published
2021
Full Text
View/download PDF

9. Efficacy of ibrutinib in the treatment of Bing–Neel syndrome

Author

Cabannes-Hamy, Aurélie, Lemal, Richard, Goldwirt, Lauriane, Poulain, Stéphanie, Amorim, Sandy, Pérignon, Renan, Berger, Juliette, Brice, Pauline, De Kerviler, Eric, Bay, Jacques-Olivier, Sauvageon, Helene, Beldjord, Kheira, Mourah, Samia, Tournilhac, Olivier, and Thieblemont, Catherine

Published
2016
Full Text
View/download PDF

10. Azole resistance of Aspergillus fumigatus in immunocompromised patients with invasive Aspergillosis

Author

Alanio, Alexandre, Denis, Blandine, Hamane, Samia, Raffoux, Emmanuel, de Latour, Regis Peffault, Menotti, Jean, Amorim, Sandy, Touratier, Sophie, Bergeron, Anne, and Bretagne, Stephane

Subjects
Aspergillus -- Physiological aspects -- Research, Microbial drug resistance -- Research, Aspergillosis -- Drug therapy -- Research, Health
Abstract

To the Editor: First-line antifungal therapy for invasive aspergillosis (IA) is voriconazole, which is challenged by the emergence of azole resistance (1). A recent article reported a 3.2% prevalence of [...]

Published
2016

11. Outcome of Patients Receiving Venetoclax for Chronic Lymphocytic Leukemia (CLL) in Real-Life Clinical Practice: Results of the French ATU Program on Behalf of the Filo Group

Author

Bouclet, Florian, primary, Calleja, Anne, additional, Dilhuydy, Marie-Sarah, additional, Amorim, Sandy, additional, Cymbalista, Florence, additional, Herbaux, Charles, additional, de Guibert, Sophie, additional, Roos-Weil, Damien, additional, Hivert, Benedicte, additional, Aurran, Thérèse, additional, Dupuis, Jehan, additional, Blouet, Anaise, additional, Tchernonog, Emmanuelle, additional, Laribi, Kamel, additional, Dmytruk, Natalia, additional, Morel, Pierre, additional, Michallet, Anne-Sophie, additional, Dartigeas, Caroline, additional, Farnault, Laure, additional, Lavaud, Anne, additional, Plantier, Isabelle, additional, Bay, Jacques-Olivier, additional, Tournilhac, Olivier, additional, Delmer, Alain Jacques, additional, Feugier, Pierre, additional, Ysebaert, Loic, additional, and Guieze, Romain, additional

Published
2018
Full Text
View/download PDF

12. The value of molecular techniques to diagnose Ureaplasma urealyticum and Nocardia farcinica pleuropneumonia in a patient with diffuse large B-cell lymphoma

Author

Canouï, Etienne, primary, Blanc, Kim, additional, Loubinoux, Julien, additional, Valade, Sandrine, additional, Hamard, Cécile, additional, Lefebvre, Aurélie, additional, Amorim, Sandy, additional, Bébéar, Cécile, additional, Rodriguez-Nava, Veronica, additional, Lebeaux, David, additional, Launay, Odile, additional, Alifano, Marco, additional, Rabbat, Antoine, additional, and Kernéis, Solen, additional

Published
2017
Full Text
View/download PDF

16. Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?

Author

Bigenwald, Camille, primary, Harel, Stephanie, additional, Chevillon, Florian, additional, Roos-Weil, Damien, additional, Bernard, Olivier A., additional, Amorim, Sandy, additional, Brice, Pauline, additional, Lionel, Ades, additional, Nloga, Anne Marie, additional, Sébert, Marie, additional, Braun, Thorsten, additional, Eclache, Virginie, additional, Thieblemont, Catherine, additional, and Fenaux, Pierre, additional

Published
2015
Full Text
View/download PDF

17. Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Author

Richez, Valentine, primary, Abraham, Julie, additional, Amorim, Sandy, additional, Herbaux, Charles, additional, Philippe, Laure, additional, Andre, Marc, additional, Parcelier, Anne, additional, Fruchart, Christophe, additional, Bouabdallah, Krimo, additional, Cornillon, Jérôme, additional, Cherrier, Sigrid, additional, Salvado, Clementine, additional, Drenou, Bernard, additional, Oberic, Lucie, additional, Quittet, Philippe, additional, Venton, Geoffroy, additional, Calmettes, Claire, additional, Chebrek, Safia, additional, Rossi, Cedric, additional, Campidelli, Arnaud, additional, Lioure, Bruno, additional, Auger, Sophie, additional, Altounian, Lucille, additional, Mineur, Philippe, additional, Woff, Erwin, additional, and Peyrade, Frederic, additional

Published
2015
Full Text
View/download PDF

18. A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

Author

Thieblemont, Catherine, primary, Stathis, Anastasios, additional, Inghirami, Giorgio, additional, Karlin, Lionel, additional, Morschhauser, Franck, additional, Gleeson, Mary, additional, Broussais, Florence, additional, Amorim, Sandy, additional, Salles, Gilles, additional, Facon, Thierry, additional, Cunningham, David, additional, Vey, Norbert, additional, Bourdel, Fabrice, additional, Herait, Patrice, additional, and Zucca, Emanuele, additional

Published
2014
Full Text
View/download PDF

21. Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.

Author

Carras S, Torroja A, Emadali A, Montaut E, Daguindau N, Tempescul A, Moreau A, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Barbieux S, Corm S, Banos A, Fouillet L, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouabdallah K, Amorim S, Garidi R, Voillat L, Joly B, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Burroni B, Callanan M, Le Gouill S, and Gressin R

Subjects
Humans, Aged, Female, Male, Aged, 80 and over, Prognosis, Rituximab therapeutic use, Rituximab administration & dosage, Treatment Outcome, Bendamustine Hydrochloride administration & dosage, Bendamustine Hydrochloride therapeutic use, Dexamethasone therapeutic use, Dexamethasone administration & dosage, Doxorubicin therapeutic use, Doxorubicin administration & dosage, Lymphoma, Mantle-Cell drug therapy, Lymphoma, Mantle-Cell genetics, Lymphoma, Mantle-Cell mortality, Lymphoma, Mantle-Cell pathology, Tumor Suppressor Protein p53 genetics, Mutation, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Hypoalbuminemia etiology
Abstract

Between 2011 and 2012, a phase II trial evaluated the use of the RiBVD (rituximab, bendamustine, velcade and dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients over the age of 65. We have now re-examined the classic prognostic factors, adding an assessment of TP53 mutation status. Patients (N=74; median age 73 years) were treated with the RiBVD combination. Median progression-free survival (mPFS) was 79 months and median overall survival (mOS) was 111 months. TP53 mutation status was available for 54/74 (73%) patients. TP53 mutations (TP53mt) were found in 12 patients (22.2%). In multivariate analysis, among the prognostic factors (PF) evaluated, only TP53mt and an albumin level (Alb) 3.6 g/dL were independently associated with a shorter mPFS. A hazard ratio (HR) of 3.16 (1.3-9.9, P=0.014) was obtained for TP53mt versus TP53 wild-type (wt), and 3.6 (1.39-9.5, P=0.009) for Alb <3.6 g/dL versus Alb ≥3.6 g/dL. In terms of mOS, multivariate analysis identified three PF: TP53mt (HR: 5.9 [1.77-19.5, P=0.004]), Alb <3.6 g/dL (HR: 5.2 [1.46- 18.5, P=0.011]), and ECOG=2 (HR: 3.7 [1.31-10.6, P=0.014]). Finally, a score combining TP53 status and Alb distinguished three populations based on the presence of 0, 1, or 2 PF. For these populations, mPFS was 7.8 years, 28 months, and 2.5 months, respectively. Our prolonged follow-up confirmed the efficacy of the RiBVD regimen, comparing it favorably to other regimens. TP53mt and hypoalbuminemia emerge as strong PF that can be easily integrated into prognostic scores for older adult patients with MCL.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results